Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health Inc (NQ: JAGX )

0.2810 -0.0360 (-11.36%)
Streaming Delayed Price Updated: 3:04 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Jaguar Health Inc

< Previous 1 2 3 4 5 6 7 8 Next >
REMINDER: Napo Pharmaceuticals, a Jaguar Health Company, Supports Gay Men's Health with Participation in Pineapple Healthcare's "Butt Stuff Brunch with Dr. Carlton" August 5th
Via ACCESSWIRE
Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug (IND) Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome (SBS)
Via ACCESSWIRE
In Honor of World Nature Conservation Day, Jaguar Health Announces Planting of More Than 1.1 Million Trees in Peruvian Amazon
Via ACCESSWIRE
Jaguar Health Names Principal Investigators for Clinical Trial to Support Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Via ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Company, Supports Gay Men's Health with Participation in Pineapple Healthcare's "Butt Stuff Brunch with Dr. Carlton"
Via ACCESSWIRE
Jaguar Health Reports Approval of All Proposals at 2023 Annual Meeting of Stockholders
Via ACCESSWIRE
Jaguar Health Subsidiary Becomes Corporate Partner of Multinational Association of Supportive Care in Cancer (MASCC)
Via ACCESSWIRE
Canine and Child Cancer Research Advocates Call for Support as Capitol Hill "Goes to the Dogs"
Via ACCESSWIRE
Take C.H.A.R.G.E. Registry Marks One-Year Anniversary on National Canine Cancer Awareness Day, With Database Grown 40%
Via ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Company, Submits Investigational New Drug (IND) Application to FDA for Microvillus Inclusion Disease
Via ACCESSWIRE
First U.S.-Based Canine Cancer Registry, Founded by Jaguar Health, Joins International Network to Help Advance Canine and Human Cancer Research
Via ACCESSWIRE
Jaguar Health Launching AI-Driven Social Media Disease Awareness Education Series Regarding Cancer Therapy-Related Diarrhea in Dogs and People
Via ACCESSWIRE
Jaguar Health to Present June 21st at MedInvest Oncology Investor Conference
Via ACCESSWIRE
Ladenburg Thalmann to Host Virtual Discussion June 22nd with Jaguar Health CEO and Leading Patient Advocates on Impact of Cancer Therapy-related Diarrhea on Patients & Importance of the Patient Voice in Supportive Care
Via ACCESSWIRE
Jaguar Health Reports First Quarter 2023 Financial Results
Via ACCESSWIRE
Jaguar Health Launches AI-powered Web Portal to Support Patient Access to Mytesi, the Company's FDA-approved Prescription Drug
Via ACCESSWIRE
Jaguar Completes Enrollment in Its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea
Via ACCESSWIRE
Napo Therapeutics Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress in Abu Dhabi
Via ACCESSWIRE
European Pharmaceutical Industry Leader and Entrepreneur Massimo Radaelli, PhD Named Commander of the Italian Republic for Special Merits
Via ACCESSWIRE
Jaguar Announces Over-Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea
Via ACCESSWIRE
Board Certified Patient Advocate Stacey Tinianov, MPH, Joins Jaguar Health's Scientific Advisory Board
Via ACCESSWIRE
Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
Jaguar Health to Present at Lytham Partners Spring 2023 Investor Conference & Participate in Animal Health Panel
Via ACCESSWIRE
Canalevia-CA1, Jaguar Animal Health’s FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs, Now Available from Chewy
Via ACCESSWIRE
U.S. Veterinary Oncologists Participating in a New Survey Prefer Canalevia-CA1 Over the Current Standard of Care
Via ACCESSWIRE
Patient Enrollment Surpasses 90% in Jaguar Health's Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea
Via ACCESSWIRE
Jaguar Health to Hold Investor Webcast Monday, May 15th at 8:30 AM EDT Regarding Q1 2023 Financials & Corporate Updates
Via ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
Jaguar Health Provides Update on Monitoring Trading Activity to Identify Possible Illegal Short Selling
Via ACCESSWIRE
Jaguar Animal Health Exhibiting at Veterinary Cancer Society Collaborative Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.